Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Aggen

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
European Urology|October 19, 2024
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
European Urology|May 23, 2024
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 TrialKelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
European Urology Oncology|November 9, 2023
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney CancerRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
European Urology Oncology|March 30, 2025
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell CarcinomaRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World ExperienceBrendan J Guercio, Michal Sarfaty, Min Yuen Teo, et al.
Journal for Immunotherapy of Cancer|March 3, 2021
Considerations for treatment duration in responders to immune checkpoint inhibitorsThomas U Marron, Aideen E Ryan, Sangeetha M Reddy, et al.
Nature Communications|December 20, 2025
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancerZiyu Chen, Xinran Tang, Jordan E Eichholz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2026
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancerBrendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran, et al.
European Urology|November 16, 2024
Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial CarcinomaKwanghee Kim, Syed M Alam, Fengshen Kuo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2025
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder CancerAndrea Necchi, Matthew D Galsky, Nazli Dizman, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
European Urology|October 19, 2024
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
European Urology|May 23, 2024
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 TrialKelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
European Urology Oncology|November 9, 2023
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney CancerRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
European Urology Oncology|March 30, 2025
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell CarcinomaRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2023
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World ExperienceBrendan J Guercio, Michal Sarfaty, Min Yuen Teo, et al.
Journal for Immunotherapy of Cancer|March 3, 2021
Considerations for treatment duration in responders to immune checkpoint inhibitorsThomas U Marron, Aideen E Ryan, Sangeetha M Reddy, et al.
Nature Communications|December 20, 2025
Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancerZiyu Chen, Xinran Tang, Jordan E Eichholz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2026
Neoadjuvant nivolumab with or without ipilimumab for cisplatin-ineligible patients with muscle-invasive bladder cancerBrendan J Guercio, Eugene J Pietzak, Vignesh Ravichandran, et al.
European Urology|November 16, 2024
Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial CarcinomaKwanghee Kim, Syed M Alam, Fengshen Kuo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2025
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder CancerAndrea Necchi, Matthew D Galsky, Nazli Dizman, et al.
Pageof 3